StockData

Aclaris Therapeutics vs Zenas BioPharma

ACRS and ZBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACRS and ZBIO compare

Zenas BioPharma is the larger company, worth 3.6 times as much as Aclaris Therapeutics ($1.8B against $498M).

Aclaris Therapeutics scores higher on the StockData Score (5 against 1 for Zenas BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACRSZBIO
Size and price
Market cap$498M$1.8B
Share price$3.38$27.75
Change, 1 year34.1%−20.7%
Change, 5 years−73.2%–
Beta (5Y)1.040.25
Employees73167
StockData Score
Total score5 (better)1
Valuation score00
Growth score00
Performance score00
Health score5 (better)1
Dividend score00
Valuation
P/S60.5×–
P/B4.0× (better)8.5×
FCF yield−12.5% (better)−13.4%
Fair value$1.42–
Margin of safety−138%–
Growth
Revenue growth (TTM)−51.0%–
Revenue growth, 5Y average3.8%–
Profitability
Gross margin79.5%–
Operating margin−1050%–
Net margin−921%–
FCF margin−757%–
Return on equity−59.1% (better)−265%
Financial health
Debt / equity0.001.05 (better)
Current ratio3.469.42 (better)
Altman Z-score−3.52−1.48 (better)
Piotroski F-score3 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions82.3%94.0%
Held by insiders13.3%36.1%
Insider net buying, 12 months−$1.4M$11.4M (better)
Short interest, % of float9.1%27.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.